About the
News & EventsAlumni
& Giving
Make a Gift

News Release (Back to Menu)

May 15 Pharma Industry Forum to Explore Impact of Recent Legal Developments on Pharmaceutical Industry

April 22, 2009 – 

With recent court decisions and government activities in the U.S. and Europe having a real and immediate impact on how the pharmaceutical industry conducts business, Rutgers School of Law–Newark and the international business law firm Sidley Austin LLP have teamed up to sponsor Pharma Industry Forum on Friday, May 15, 2009 at the law school. The all-day event will feature a series of three interactive panels including federal judges, top pharmaceutical industry attorneys, and representatives of the Federal Trade Commission and the European Commission.

To register for Pharma Industry Forum, please RSVP to rsvp@sidley.com by May 8.

Philip S. Johnson, Chief Intellectual Property Counsel, Johnson & Johnson, will be the keynote speaker. Confirmed panelists include:

  • Hon. Gregory M. Sleet, Chief Judge, U.S. District Court for the District of Delaware
  • Hon. Joseph A. Greenaway, Jr., Judge of the U.S. District Court for the District of New Jersey
  • Hon. Madeline Cox Arleo, U.S. Magistrate Judge for the District of New Jersey
  • Henry Hadad, VP & Associate General Counsel, Intellectual Property, Schering-Plough
  • Sherry Knowles, SVP & Chief Intellectual Property Counsel, GlaxoSmithKline
  • Patricia C. Lukens, Assistant General Counsel for Johnson & Johnson and VP Law, Internal Medicine Division, Ortho-McNeil-Janssen Pharmaceuticals
  • Shu Lee, Ph.D., VP, Intellectual Property and Legal Affairs, SuperGen, Inc.
  • Markus H. Meier, Assistant Director, Bureau of Competition, Health Care Division, Federal Trade Commission
  • Fabio Domanico, Assistant Case Handler, Pharmaceuticals Sector Inquiry Task Force, Directorate-General for Competition, European Commission
  • Sumanth Addanki, Senior Vice President, NERA Economic Consulting

The panels, which will encourage audience participation, will explore:

  • Judges’ Panel: The latest developments and pressing issues facing litigants involved in pharmaceutical patent litigation.
  • U.S. and European Regulators: Antitrust concerns and current enforcement priorities.
  • In-house Counsel Panel: The most challenging new issues, including decisions with the greatest impact on their practices.

The event will include light breakfast, lunch and a reception following the program.